AQUAMEPHYTON Drug Patent Profile
✉ Email this page to a colleague
When do Aquamephyton patents expire, and when can generic versions of Aquamephyton launch?
Aquamephyton is a drug marketed by Pai Holdings Pharm and is included in one NDA.
The generic ingredient in AQUAMEPHYTON is phytonadione. There are ten drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the phytonadione profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aquamephyton
A generic version of AQUAMEPHYTON was approved as phytonadione by AMNEAL PHARMS CO on May 11th, 2018.
US Patents and Regulatory Information for AQUAMEPHYTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pai Holdings Pharm | AQUAMEPHYTON | phytonadione | INJECTABLE;INJECTION | 012223-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pai Holdings Pharm | AQUAMEPHYTON | phytonadione | INJECTABLE;INJECTION | 012223-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
